Join to View Full Profile
309 W Quinto StSanta Barbara, CA 93105
Phone+1 805-563-0041
Fax+1 805-563-0051
Dr. Greenwald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2007- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2000 - 2003
Stanford University School of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2001 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
- Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Publications & Presentations
PubMed
- 121 citationsPhase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M. Barr, Gene Brian Saylors, Stephen E. Spurgeon, Bruce D. Cheson, Daniel Reif Greenwald
Blood. 2016-05-19 - 11 citationsA phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)Daniel R. Greenwald, Hailun Li, Selina M. Luger, Ronald S. Go, David King
Journal of Hematology & Oncology. 2013-07-05 - 790 citationsCoadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.Kazuki N. Sugahara, Tambet Teesalu, Priya Prakash Karmali, Venkata Ramana Kotamraju, Lilach Agemy
Science. 2010-05-21
Press Mentions
Welcome to the ’Hood - Santa Barbara News-PressMarch 29th, 2021- UCLA Making Big Mark in Santa Barbara Medical MarketFebruary 24th, 2021
- UCLA Health Opens New Cancer Center in Santa BarbaraFebruary 11th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
